IDH1 and central nervous system cancer: As IDH-mutant inhibitors decrease seizure frequency in mice bearing IDH-mutant gliomas (126), future clinical trials with IDH-mutant inhibitors (137) should include seizure frequency outcomes as a priority endpoint.